Literature DB >> 20589705

Preoperative clinically inapparent leucopenia in patients undergoing neoadjuvant chemotherapy for locally advanced gastric cancer is not a risk factor for surgical or general postoperative complications.

Daniel Reim1, Norbert Hüser, Daniela Humberg, Alexander Novotny, Volker Assfalg, Edouard Matevossian, Helmut Friess, Christoph Schuhmacher.   

Abstract

BACKGROUND: Since the recent MAGIC trial neoadjuvant chemotherapy has been considered as treatment option for patients with advanced gastric cancer for tumor-downsizing and increasing R0 resection rates. Morbidity was reported in 45% of the patients treated within this randomized trial. Due to myelotoxicity under chemotherapy a part of the patients might undergo surgery with preoperative leucopenia. As leucopenia causes adverse events such as opportunistic infections and fever, it might be considered as a relevant risk factor in the course of surgical treatment. PATIENTS AND METHODS: We analyzed a cohort of neoadjuvantly treated patients (n = 214), which had a clinically inapparent but proven leucopenia (n = 58) before undergoing surgery due to advanced stage gastric cancer.
RESULTS: Statistical analysis by Fisher's exact test showed, that there was no significant effect neither on general (P = 0.191) nor on surgery-dependant postoperative complications (P = 0.75).
CONCLUSION: Conclusively patients with clinically inapparent leucopenia after neoadjuvant chemotherapy due to advanced stage gastric cancer can be safely operated on without putting them in danger of relevant surgical complications. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20589705     DOI: 10.1002/jso.21622

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

1.  Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy.

Authors:  Shuang-Xi Li; Sang Hyuk Seo; Yoon Young Choi; Masatoshi Nakagawa; Ji Yeong An; Hyoung-Il Kim; Jae-Ho Cheong; Woo Jin Hyung; Sung Hoon Noh
Journal:  BMC Cancer       Date:  2016-01-19       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.